Sat, Aug 23, 2014, 3:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Forest Laboratories Inc. Message Board

  • lost_space_ranger lost_space_ranger Jul 18, 2013 6:51 AM Flag

    frx

    may be a seller not a buyer- they have 10 new drugs coming to mkt this year. Their sales force is too small to take advantage of the opportunity.

    It may be up for sale- CEO going- Icahn in the wings

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Where do you get this incorrect info? What are your sources? Lol

      Sentiment: Hold

    • No one in the right mind would by FRX, they have no know how to speak of and bunch of mee-too drugs that are expiring one by one. They are hoping IBS drug will get some money in, but the rest of the #$%$ they push through FDA are all old news drugs that are no better than existing #$%$. They going to be losing revenues and cash because their CEO has no vision and VP of clinical is a Soviet-style bureaucrat with zero ideas. One cannot be competitive in Pharma world by producing aspirin.

      • 1 Reply to karzoff
      • analyst rept

        • I Forest Labs is in a unique situation where it has too many new drugs to launch. Among
        its ..........drugs the company assembled to replace Lexapro and
        Namenda, 7 have been launched: Bystolic, Savella, Viibryd, Teflaro,
        Linzess, Daliresp and Tudorza. The other 2 ,
        levomilnacipran has a PDUFA date this month, while cariprazine is also
        under FDA review. ..... Forest has also just launched Namenda
        XR, ............ it is likely the 3 co-formulated
        drugs, Tudorza + formoterol, Bystolic + valsartan, and ceftazidime +
        avibactam, will reach the US market in the near future.
        Tudorza + formoterol will be filed for FDA approval by the end of this
        year. , FRX is potentially introducing 13 new drugs into the
        US branded pharma mkt

    • Frx has the largest sales force, numbers wise, in the industry right now. They do not have 10 new drugs coming this year - they already promote 8 and have maybe 1 coming this year and 1 next year.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.